Overview

Individuals with both rare and common underlying lung conditions suffer from frequent bacterial infections, causing pulmonary exacerbations (lung ‘flare ups’) that lead to worsening lung function and necessitate multiple courses of antibiotics. Some of the most problematic bacterial species causing these infections are Pseudomonas aeruginosa and non-tuberculous mycobacteria (NTM).

Treatment options are poor (i.e. intolerance and toxicity issues) and tests are not fit for purpose, relying on sputum culture which can take up to several months for the most slow-growing bacteria.

New tests are required to monitor infection in a more sensitive, quantitative and reliable way to enable more effective treatment decisions and clearer assessment of new treatments going through clinical trials.

We are developing molecular tests to quantify P. aeruginosa and NTM infections. Working on the same principle as our TB test (TB-MBLA: A potential test for both diagnosis and monitoring of tuberculosis over time – LifeArc) the assay works by targeting ribosomal RNA, a molecule abundantly present in live bacterial cells. With results available in several hours, these tests are designed to provide quantitative information in a substantially shorter time frame than sputum culture and have increased sensitivity and reproducibility.

Where are we now?

Feasibility has been concluded, with formal verification (under ISO13485 certification) expected to be underway by early 2026, which will provide quantitative monitoring tools for use in clinical trials and/or to support clinical decisions.

Clinical data generation for all tests is ongoing and through collaborations with NTM clinical experts, we are planning to implement our assays in various studies or trials, which will demonstrate the clinical utility of our tests.